GC Biopharma Corp. (KRX:006280)
126,400
-1,000 (-0.78%)
Last updated: Mar 28, 2025
GC Biopharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
Operating Revenue | 1,679,892 | 1,626,644 | 1,711,313 | 1,537,826 | 1,504,115 | Upgrade
|
Other Revenue | - | -0 | -0 | -0 | - | Upgrade
|
Revenue | 1,679,892 | 1,626,644 | 1,711,313 | 1,537,826 | 1,504,115 | Upgrade
|
Revenue Growth (YoY) | 3.27% | -4.95% | 11.28% | 2.24% | 10.83% | Upgrade
|
Cost of Revenue | 1,199,348 | 1,143,313 | 1,131,350 | 1,018,585 | 1,064,691 | Upgrade
|
Gross Profit | 480,544 | 483,331 | 579,962 | 519,240 | 439,425 | Upgrade
|
Selling, General & Admin | 265,470 | 258,898 | 292,484 | 282,771 | 242,918 | Upgrade
|
Research & Development | 166,198 | 173,487 | 191,347 | 146,030 | 137,987 | Upgrade
|
Other Operating Expenses | 1,277 | 1,624 | 2,165 | 1,594 | 1,259 | Upgrade
|
Operating Expenses | 448,505 | 449,420 | 499,253 | 445,515 | 389,239 | Upgrade
|
Operating Income | 32,039 | 33,911 | 80,710 | 73,726 | 50,186 | Upgrade
|
Interest Expense | -40,439 | -28,483 | -18,393 | -12,501 | -10,354 | Upgrade
|
Interest & Investment Income | 3,621 | 3,421 | 3,785 | 1,665 | 1,555 | Upgrade
|
Earnings From Equity Investments | 1,250 | - | 40,467 | - | - | Upgrade
|
Currency Exchange Gain (Loss) | 7,245 | 1,010 | 2,570 | 13,477 | -17,517 | Upgrade
|
Other Non Operating Income (Expenses) | -1,440 | 3,147 | -4,842 | 8,002 | -913.65 | Upgrade
|
EBT Excluding Unusual Items | 2,276 | 13,006 | 104,296 | 84,368 | 22,956 | Upgrade
|
Gain (Loss) on Sale of Investments | -20,799 | -37,222 | -18,759 | 81,200 | 31,038 | Upgrade
|
Gain (Loss) on Sale of Assets | -3,761 | -2,919 | 190 | 6,991 | 58,619 | Upgrade
|
Asset Writedown | -18,088 | - | - | - | -8,140 | Upgrade
|
Other Unusual Items | -738 | - | - | - | - | Upgrade
|
Pretax Income | -41,110 | -27,135 | 85,728 | 172,559 | 104,474 | Upgrade
|
Income Tax Expense | 1,527 | -7,326 | 16,313 | 35,609 | 15,366 | Upgrade
|
Earnings From Continuing Operations | -42,637 | -19,809 | 69,415 | 136,950 | 89,108 | Upgrade
|
Earnings From Discontinued Operations | - | - | - | - | 162.96 | Upgrade
|
Net Income to Company | -42,637 | -19,809 | 69,415 | 136,950 | 89,271 | Upgrade
|
Minority Interest in Earnings | 16,357 | -6,823 | -3,962 | -13,738 | -8,222 | Upgrade
|
Net Income | -26,280 | -26,632 | 65,453 | 123,212 | 81,049 | Upgrade
|
Net Income to Common | -26,280 | -26,632 | 65,453 | 123,212 | 81,049 | Upgrade
|
Net Income Growth | - | - | -46.88% | 52.02% | - | Upgrade
|
Shares Outstanding (Basic) | 11 | 11 | 11 | 5 | 11 | Upgrade
|
Shares Outstanding (Diluted) | 11 | 11 | 11 | 5 | 11 | Upgrade
|
Shares Change (YoY) | -0.03% | 0.02% | 125.85% | -55.72% | - | Upgrade
|
EPS (Basic) | -2303.00 | -2333.00 | 5734.87 | 24381.79 | 7101.34 | Upgrade
|
EPS (Diluted) | -2303.00 | -2333.00 | 5734.87 | 24381.79 | 7101.34 | Upgrade
|
EPS Growth | - | - | -76.48% | 243.34% | - | Upgrade
|
Free Cash Flow | -85,452 | -84,560 | 61,158 | 23,658 | -46,902 | Upgrade
|
Free Cash Flow Per Share | -7488.36 | -7407.62 | 5358.56 | 4681.52 | -4109.46 | Upgrade
|
Gross Margin | 28.61% | 29.71% | 33.89% | 33.77% | 29.22% | Upgrade
|
Operating Margin | 1.91% | 2.08% | 4.72% | 4.79% | 3.34% | Upgrade
|
Profit Margin | -1.56% | -1.64% | 3.82% | 8.01% | 5.39% | Upgrade
|
Free Cash Flow Margin | -5.09% | -5.20% | 3.57% | 1.54% | -3.12% | Upgrade
|
EBITDA | 113,074 | 109,810 | 145,806 | 129,630 | 98,977 | Upgrade
|
EBITDA Margin | 6.73% | 6.75% | 8.52% | 8.43% | 6.58% | Upgrade
|
D&A For EBITDA | 81,034 | 75,899 | 65,096 | 55,904 | 48,791 | Upgrade
|
EBIT | 32,039 | 33,911 | 80,710 | 73,726 | 50,186 | Upgrade
|
EBIT Margin | 1.91% | 2.08% | 4.72% | 4.79% | 3.34% | Upgrade
|
Effective Tax Rate | - | - | 19.03% | 20.64% | 14.71% | Upgrade
|
Advertising Expenses | 35,238 | 40,739 | 50,726 | 49,015 | 39,770 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.